Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 369-377

  Sugaya, Norio ^a   Kohno, Shigeru ^b   Ishibashi, Toru ^c   Wajima, Toshihiro ^c   Takahashi, Takao ^d  

^a Keiyu Hospital   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PERAMIVIR;

2009 H1N1 INFLUENZA; ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ADOLESCENT; ARTICLE; CHILD; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; HUMAN; INFANT; KETONURIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; JAPAN; MALE; NEURAMINIDASE; PANDEMICS; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 84455192539     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00132-11     Document Type: Article

References (36)

1. Armitage P. 1955. Tests for linear trends in proportions and frequencies. Biometrics 11:375-386.
2. Bantia S, et al. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. (Pubitemid 32230997)
3. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir. Res. 69:39-45. (Pubitemid 41790480)
4. Birch MW. 1965. The detection of partial association II: the general case. J. R. Stat. Soc. Ser. B Stat. Methodol. 27:111-124.
5. Birnkrant D, Cox E. 2009. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204 -2207.
6. Centers for Disease Control Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433- 435.
7. 2tests. Biometrics 10:417-451.
8. Division of Acquired Immunodeficiency Syndrome, NIAID, NIH. December 2004, posting date. Division of AIDS table for grading the severity of adult and pediatric adverse events. NIH, Bethesda, MD. http://www.niaid.nih.gov/ labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtable.pdf.
9. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495. (Pubitemid 27265649)
10. Gubareva LV, Webster RG, Hayden FG. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45:3403-3408. (Pubitemid 33107853)
11. Hayden F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48:S3-S13.
12. Holford NHG. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332. (Pubitemid 26177179)
13. Iris WL, et al. 2010. The natural viral load profile of patients with pandemic 2009 influenza A (H1N1) and the effect of oseltamivir treatment. Chest 137:759-768.
14. Jain S, et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361:1935-1944.
15. Kawai N, et al. 2007. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J. Infect. 55:267-272. (Pubitemid 47248483)
16. Kiso M, et al. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
17. Khandaker G, et al. 2011. Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir. Viruses 5:148 -156.
18. Klein JP, Moeschberger ML. 1997. Survival analysis: techniques for censored and truncated data, sect 7.4. Springer-Verlag, New York, NY.
19. Kohno S, Kida H, Mizuguchi M, Shimada J, for the S-021812 Clinical Study Group. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54:4568-4574.
20. Kohno S, et al. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob. Agents Chemother. 55:2803-2812.
21. Kohno S, et al. 2011. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob. Agents Chemother. 55:5267-5276.
22. Libster R, et al. 2010. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N. Engl. J. Med. 362:45-55.
23. Mantel N. 1964. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc. 58:690-700.
24. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515- 4520.
25. Potier M, Mameli L, Belislem M, Dallaire L, Melanxon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyla-D-N- acetylneuraminate) substrate. Anal. Biochem. 94:287-296. (Pubitemid 9173017)
26. Rhodin MM, et al. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24:67-76.
27. Schwartz GJ, Brion LP, Spitzer A. 1987. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. North. Am. 34:571-590. (Pubitemid 17080631)
28. Shionogi & Co., Ltd. 2010. Rapiacta® for intravenous drip infusion: package insert. Shionogi & Co., Ltd, Osaka, Japan. (In Japanese.)
29. Sugaya N, et al. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202. (Pubitemid 46079980)
30. Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. 2006. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab. Pharmacokinet. 21:324-331.
31. U.S. Food and Drug Administration. 2009. News and Events: FDA authorizes emergency use of intravenous antiviral peramivir for 2009 H1N1 influenza for certain patients, settings. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm187813.htm. U.S. Food and Drug Administration, Washington, DC.
32. U.S. Food and Drug Administration. 1998. FDA guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products, November 1998. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf. U.S. Food and Drug Administration, Washington, DC.
33. World Health Organization. 2009. Global alert and response (GAR): pandemic (H1N1) 2009, update 111. http://www.who.int/csr/don/2010-07-30/en/ print.html. World Health Organization, Geneva, Switzerland.
34. World Health Organization. 2010. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 viruses. http://www.who.int/csr/disease/ swineflu/oseltamivirresistant20100305.pdf. World Health Organization, Geneva, Switzerland.
35. World Health Organization. 2010. WHO Guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses, revised February 2010. http://www.who.int/csr/resources/publications/swineflu/ h1n1-guidelines-pharmaceutical-mngt.pdf. World Health Organization, Geneva, Switzerland.
36. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.